Literature DB >> 24242220

Cataract formation: a possible complication of intra-arterial chemotherapy for retinoblastoma.

Daniela Suesskind1, Merle Schrader, Michael H Foerster, Ulrike Ernemann, Sabine Aisenbrey.   

Abstract

PURPOSE: To delineate and discuss a not yet described possible ocular complication of selective intra-arterial chemotherapy (SIAC) for treatment of retinoblastoma.
METHODS: A 23-month-old girl with a large unilateral retinoblastoma was treated with repeated SIAC using 5 mg melphalan between July 2010 and January 2012. Clinical course of tumor and further ocular changes after therapy and histopathologic findings are described.
RESULTS: In total, 5 SIAC were performed over a time period of 18 months. After the last SIAC, diffuse dense cataract prevented further funduscopy. In addition, anterior chamber seeding was obvious, leading to the decision to enucleate the eye. Histopathologically, nearly complete regression of the main tumor mass with prominent calcifications, but vital tumor seeding in the vitreous, on the lens surface, on the ciliary body, and in the anterior chamber, was observed. Peculiar vacuolation of the lens epithelial cells, liquefaction of the subepithelial lens fibers, and diffuse small vacuoles within the lens were striking.
CONCLUSIONS: Repeated SIAC with melphalan may induce cataract formation, possibly as a toxic effect of the chemotherapeutic to the lens, maybe combined with radiation exposure during fluoroscopy. This ocular complication should be taken into consideration as a limitation of the number of feasible repeated treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24242220     DOI: 10.5301/ejo.5000393

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  5 in total

1.  Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell.

Authors:  Yan-Dong Wang; Yong-Jing Su; Jian-Ying Li; Xiang-Chao Yao; Guang-Jiang Liang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.

Authors:  Yan-Dong Wang; Yong-Jing Su; Jian-Ying Li; Xiang-Chao Yao; Guang-Jiang Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue.

Authors:  Sandrine Haghiri; Chiraz Fayech; Imène Mansouri; Christelle Dufour; Claudia Pasqualini; Stéphanie Bolle; Sophie Rivollet; Agnès Dumas; Amel Boumaraf; Amel Belhout; Neige Journy; Vincent Souchard; Giao Vu-Bezin; Cristina Veres; Nadia Haddy; Florent De Vathaire; Dominique Valteau-Couanet; Brice Fresneau
Journal:  Bone Marrow Transplant       Date:  2021-04-06       Impact factor: 5.174

Review 4.  Risk definition and management strategies in retinoblastoma: current perspectives.

Authors:  Fariba Ghassemi; Alireza Khodabande
Journal:  Clin Ophthalmol       Date:  2015-06-08

5.  Antitumor effect of Quercetin on Y79 retinoblastoma cells via activation of JNK and p38 MAPK pathways.

Authors:  Haojie Liu; Ming Zhou
Journal:  BMC Complement Altern Med       Date:  2017-12-13       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.